(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 August 2024 (15.08.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/166009 A1

(51) International Patent Classification:
A61K 31/497 (2006.01) *A61P 13/12* (2006.01)
A61K 31/7034 (2006.01)

(21) International Application Number:
PCT/IB2024/051125

(22) International Filing Date:
07 February 2024 (07.02.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/483,831	08 February 2023 (08.02.2023)	US
63/536,599	05 September 2023 (05.09.2023)	US
63/546,955	02 November 2023 (02.11.2023)	US
63/601,540	21 November 2023 (21.11.2023)	US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151-85 Södertälje (SE).

(72) Inventors: **AMBERY, Philip**; ASTRAZENECA AB, SE-151-85 Södertälje (SE). **GREASLEY, Peter**; ASTRAZENECA AB, SE-151-85 Södertälje (SE). **MERCIER, Anne-Kristina**; ASTRAZENECA AB, SE-151-85 Södertälje (SE). **SUNNÅKER, Mikael**; ASTRAZENECA AB, SE-151-85 Södertälje (SE).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Eastbrook House, Shaftesbury Road, Cambridge Cambridgeshire CB2 8BF 6GH (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

WO 2024/166009 A1

(54) Title: COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF HIGH PROTEINURIA CHRONIC KIDNEY DISEASE

(57) Abstract: Methods for treating high proteinuria chronic kidney disease and/or at least one disease, disorder, or condition associated therewith in patients by the use of a fixed-dose combination of zibotentan and dapagliflozin are disclosed.